Technology
Identiv Announces Agreement to Sell its IoT Assets to Trackonomy, Creating a Global Physical AI and Intelligent Supply Chain Leader
Published
4 hours agoon
By
Enters into Strategic Partnership Framework Agreement to Collaborate on Future SaaS Opportunities Leveraging Trackonomy’s Physical AI Platform
Post-Close Strategy Focused on Acquiring Highly Complementary SaaS Companies to Drive Long-Term Shareholder Value
Announces $40 Million Stock Repurchase Program, with Intention to Repurchase Shares After Transaction Close
Conference Call Today at 5:00 PM EDT / 2:00 PM PDT
SANTA ANA, Calif., June 24, 2026 /PRNewswire/ — Identiv, Inc. (NASDAQ: INVE), a global leader in RFID- and Bluetooth Low Energy (BLE)-enabled Internet of Things (IoT) solutions, announced today that it has entered into a definitive agreement to sell its IoT business operating assets and its Thai subsidiary to Trackonomy Systems, Inc., a pioneer in battery-powered smart labels and a global leader in Physical AI. This transaction represents a significant milestone in the Company’s strategic evolution and positions Identiv for its next chapter of growth.
Under the terms of the agreement, Identiv will sell its IoT assets, including its German R&D center, and its Thai subsidiary, and will contribute $25 million in cash, in exchange for $50 million in Trackonomy preferred equity. Identiv’s cash contribution is intended to support integration efforts and fund incremental capital expenditures, including the scale-up of high-volume opportunities.
The two companies have also entered into a strategic partnership framework agreement to work toward a definitive agreement to collaborate on new software opportunities that leverage Trackonomy’s physical AI platform. Following the transaction close, Identiv’s strategy will focus on building a physical AI SaaS business synergistic with this platform, aiming to drive revenue growth and maximize long-term stockholder value.
Trackonomy serves major global enterprises across healthcare, airline, logistics, and manufacturing markets, as well as government. Its platform uses low-cost, cloud-connected sensors and AI to bring real-time visibility and intelligence to physical goods and assets. Privately held Trackonomy has raised over $250 million and is backed by prominent venture capital firms and investors, including 8VC, Kleiner Perkins, Koch Disruptive Technologies, and InQTel, among others.
The sale is expected to close in Q3 or early Q4 fiscal year 2026, subject to customary closing conditions, including Identiv stockholder approval at a meeting of stockholders to be scheduled. Identiv intends to remain a publicly listed company on the Nasdaq stock exchange under the ticker symbol “INVE”; however, the Identiv name and brand will be included in the sale of the IoT business operating assets, and the name of Identiv’s remaining public company will change after transaction close.
Highly Complementary Capabilities and Compelling Synergies
The two businesses have complementary products and capabilities, and Trackonomy’s acquisition of Identiv’s IoT assets is expected to create compelling strategic and operational synergies. Trackonomy’s deep expertise in large-scale deployments is expected to strengthen execution across strategic programs from Identiv. In addition, Trackonomy’s acquisition of Identiv’s operations, including its state-of-the-art Thailand manufacturing site, is intended to support Trackonomy’s growing demand for production capacity, increase utilization, and drive meaningful cost efficiencies. Overall, the transaction is expected to generate substantial synergies that Identiv believes will support its long-term strategic objectives and benefit its equity ownership in Trackonomy.
Identiv Post-Closing Strategy Targets SaaS Acquisitions to Drive Value Through Integration into Trackonomy’s Physical AI Platform
Following the sale of its IoT operations, Identiv will transition into a SaaS and physical AI-focused company. Leveraging its core expertise in RFID and BLE technologies, Identiv intends to acquire compliance SaaS companies in highly regulated industries at attractive valuations using a combination of cash and stock. Through the expected definitive strategic partnership, these acquired software assets will be integrated into Trackonomy’s physical AI data platform, enhancing the services with a physical AI data and infrastructure layer. This unique integration is intended to create immediate end-customer value and competitive differentiation, expand market reach, and contribute to revenue growth for Identiv’s acquired SaaS businesses.
Identiv is actively evaluating potential acquisition opportunities, with the objective of completing an acquisition shortly after the closing of the transaction with Trackonomy.
Leadership Commentary
“After conducting an extensive review of strategic alternatives, Identiv’s Board of Directors is pleased that the process has resulted in this unique value-creating transaction that will benefit our multiple stakeholders,” said James Ousley, Chairman of the Board of Identiv. “Our largest shareholder is supportive of this transaction and has entered into a voting agreement with the company and Trackonomy. The Identiv Board also unanimously supports this transaction and Identiv’s go-forward business strategy.”
Mr. Ousley continued, “Importantly, Identiv stockholders will be able to benefit from potential upside that may be realized from our expected strategic partnership with Trackonomy and future value creating opportunities long after transaction close.”
“I am incredibly proud that Trackonomy recognizes our team’s achievements and specialized RFID and BLE capabilities. This transaction significantly transforms the company by streamlining and reducing execution risk for Identiv’s IoT business, while preserving financial upside potential for our stockholders through participation in Identiv’s go-forward strategy and ownership interest in Trackonomy,” said Kirsten Newquist, CEO of Identiv.
“By acquiring Identiv’s IoT business assets, I believe Trackonomy can continue its growth and further enhance its position as a leading global provider of vertically integrated physical AI-based solutions across multiple industries,” said Dr. Erik Volkerink, Co-Founder and CEO of Trackonomy.
Governance and Leadership
Upon close of the transaction, Dr. Volkerink will become an observer of Identiv’s Board of Directors, and Mr. Ousley will become an observer of the Trackonomy Board. These appointments are intended to facilitate strategic alignment, continuity, oversight, and direct insight into the two companies’ strategies and execution. The Identiv Board expects the synergies between both companies to scale quickly, fostering a collaborative and mutually beneficial strategic relationship.
Furthermore, the Identiv Board intends to significantly streamline the Company’s go-forward organizational structure into a highly focused, cross-functional team dedicated to driving the new SaaS and physical AI strategy. Post-close, the Board intends to add senior leadership with deep experience in SaaS and M&A integration to lead the organization and successfully execute this next chapter of growth.
Increase in Stock Repurchase Program
Identiv’s Board of Directors has also increased the size of Identiv’s stock repurchase program to $40 million and intends to repurchase shares after the transaction closes. This reflects the Board’s belief in Identiv’s intrinsic value and the company’s priority of delivering tangible returns to its stockholders. The $40 million adds approximately $32 million to the roughly $8.1 million currently available under the stock repurchase program.
Advisors
Raymond James & Associates, Inc. is serving as Identiv’s financial advisor, and Pillsbury Winthrop Shaw Pittman LLP is serving as Identiv’s legal advisor. Cooley LLP is serving as Trackonomy’s legal advisor.
Conference Call
Identiv and Trackonomy will hold a conference call today, June 24, 2026, at 5:00 p.m. EDT (2:00 p.m. PDT) to discuss the transaction. A question-and-answer session will follow the presentation.
Toll-Free: +1 888-506-0062
International Number: +1 973-528-0011
Call ID: 831337
Webcast Link: Register and Join
The teleconference replay will be available through July 8, 2026, by dialing +1 877-481-4010 (Toll-Free Replay Number) or +1 919-882-2331 (International Replay Number) and entering passcode 54193.
If you have any difficulty connecting with the teleconference, please contact Identiv Investor Relations at IR@identiv.com.
About Identiv
Identiv’s RFID- and BLE-enabled IoT solutions create digital identities for physical objects, enhancing global connectivity for businesses, people, and the planet. Its solutions, integrated into over 2.0 billion applications worldwide, drive innovation across healthcare, logistics, consumer electronics, luxury goods, smart packaging, and more. For additional information, visit identiv.com | Follow us on LinkedIn @Identiv
About Trackonomy
Trackonomy is pioneering the next generation of Enterprise Resource Planning (ERP) for logistics and supply chain management, bringing real-time intelligence and automation from the shop floor to the top floor. Its network of interconnected assets turns inanimate objects into smart, self-optimizing systems that improve efficiency, security, and operational control. Serving major global enterprises across logistics, manufacturing, and supply chain industries, Trackonomy’s solutions optimize workflows, and provide end-to-end visibility and product condition monitoring to enhance business performance.
Note Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of management of Identiv and can be identified by words such as “anticipate,” “believe,” “continue,” “plan,” “will,” “intend,” “expect,” and similar references to the future. Any statement that is not a historical fact, including statements regarding Identiv’s strategy, opportunities, focus and goals; the expected benefits of the transaction; the terms and conditions related to the transaction, including required stockholder approvals; the expected timing and completion of the transaction; the final amount of Identiv’s expected cash contribution and the anticipated uses thereof; the potential upside from Identiv’s ownership of Trackonomy’s preferred stock, if any; the anticipated strategic partnership between Identiv and Trackonomy, including the parties’ ability to enter into a definitive agreement with respect thereto, the terms thereof, and the expected benefits; Identiv’s beliefs regarding its post-closing go-forward business model, acquisition strategy and ability to identify, complete and integrate acquisitions, on a timely basis or at all; Identiv’s intent to remain listed on Nasdaq; Identiv’s intent to implement changes to its management or organizational structure; and the timing, amount and execution of any stock repurchases, is a forward-looking statement. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, Identiv’s ability to achieve the intended benefits of the definitive strategic partnership agreement once executed; risks related to the value that may be realized from Identiv’s equity interest in Trackonomy, if any; Trackonomy’s ability to integrate the acquired assets and realize anticipated synergies, cost efficiencies and other expected benefits; Identiv’s ability to identify, complete and integrate acquisition opportunities, including delays, or at all; Identiv’s ability to implement changes to its organizational structure; the risk that the conditions to the closing of the transaction are not satisfied, including the risk that required approval of Identiv’s and Trackonomy’s stockholders are not obtained; the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement; potential litigation relating to the transaction and the effects of any outcome related thereto; the ability of each party to consummate the transaction on a timelystrati basis, or at all; the failure of the transaction to close for any reason, or in the timeframe currently anticipated; risks that the transaction disrupts current business, plans and operations of Identiv or its business prospects; competitive responses to the transaction; costs, fees or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; Identiv’s ability to continue the momentum in its business until closing; changes to the amount of cash transferred by Identiv pursuant to the transaction agreement; the parties’ ability to negotiate and enter into a definitive agreement contemplated by the strategic partnership framework agreement and the terms thereof; the ability of the expected strategic partnership, related software opportunities or future value-creating opportunities to achieve anticipated benefits; Identiv’s ability to execute its post-closing go-forward business strategy and the success thereof; risks related to the growth of the markets Identiv intends to enter; Identiv’s ability to remain listed on Nasdaq; risks related to the timing, amount and execution of any stock repurchases; diversion of management’s attention from Identiv’s business; the ability of Identiv to retain key personnel; Identiv’s ability to satisfy customer demand and expectations; the loss of customers, suppliers or partners; and the other factors discussed in its periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2025, as amended, and subsequent reports filed with the SEC. All forward-looking statements are based on information available to Identiv as of the date hereof and Identiv undertakes no obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Additional Information and Where to Find It
Identiv intends to file with the SEC a proxy statement on Schedule 14A with respect to its solicitation of proxies for approval of the transaction (the “Proxy Statement”). INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY IDENTIV AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SOLICITATION. Investors and security holders may obtain copies of these documents and other documents filed with the SEC by Identiv free of charge through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Identiv are also available free of charge in the “Investors—SEC Filings” section of Identiv’s website at ir.identiv.com/sec-filings.
Participants in the Solicitation
Identiv, its directors, director nominees, and its executive officers are or may be deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934) in the solicitation of proxies from stockholders of Identiv in connection with the transactions contemplated by the agreement.
Information about Identiv’s directors and executive officers, including compensation, is set forth in Amendment No. 1 to Identiv’s Annual Report on Form 10-K/A for the year ended December 31, 2025, filed with the SEC on April 29, 2026 (the “Amended Annual Report”), under Part III, Item 10. “Directors, Executive Officers and Corporate Governance” and Part III, Item 11. “Executive Compensation.”
Information about the ownership of common stock by Identiv’s directors and executive officers is set forth in the Amended Annual Report under Part III, Item 12. “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.” Any changes to the holdings by the directors and executive officers of Identiv securities reported in the Amended Annual Report have and will be reflected in Forms 3, 4 or 5 to be filed with the SEC, including the Form 4 filed on June 2, 2026, as well as the section entitled “Security Ownership of Certain Beneficial Owners and Management” of Identiv’s definitive Proxy Statement, and other materials to be filed with the SEC. All these documents are or will be available free of charge at the SEC’s website at www.sec.gov and in the “Investors—SEC Filings” section of Identiv’s website at ir.identiv.com/sec-filings.
In addition, each of Bleichroeder LP and Bleichroeder Holdings LLC (together, “Bleichroeder”) is or may be deemed to be a “participant” in the solicitation of proxies from stockholders of Identiv in connection with the transactions contemplated by the agreement. Information about the ownership of securities of Bleichroeder is set forth under Part III, Item 12. “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of the Amended Annual Report and Amendment No. 4 to the Schedule 13D/A filed on March 21, 2025. Any further changes will be reflected in the section entitled “Security Ownership of Certain Beneficial Owners and Management” of Identiv’s definitive Proxy Statement, and other materials to be filed with the SEC.
Identiv Investor Relations Contact:
IR@identiv.com
Identiv Media Contact:
press@identiv.com
View original content:https://www.prnewswire.com/news-releases/identiv-announces-agreement-to-sell-its-iot-assets-to-trackonomy-creating-a-global-physical-ai-and-intelligent-supply-chain-leader-302809837.html
SOURCE Identiv
You may like
Technology
ATLATL and Samsung Bioepis Launch ‘Samsung Bioepis Innovation Prize C-Lab Outside’ to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
Published
16 minutes agoon
June 25, 2026By
Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies
SHANGHAI, June 25, 2026 /PRNewswire/ — ATLATL Innovation Center (“ATLATL”), a global innovation platform for life science research and development, and Samsung Bioepis Co., Ltd., today announced the launch of the Samsung Bioepis Innovation Prize C-Lab Outside (Innovation Prize), an open innovation initiative designed to identify and support promising early-stage biotech companies across the Asia-Pacific region.
Applications for the Innovation Prize will open on June 25, 2026.
The program seeks innovative startups and emerging biotech companies working in the following therapeutic areas:
OncologyImmunology & Inflammation (I&I)Metabolic Disease
Areas of particular interest include:
Novel/New Mechanisms of Action (MoA)-based Antibody-Drug Conjugate (ADC)/ X-Drug Conjugates (XDC) (i.e., Payload, Linker, Conjugation)Antibody Engineering TechnologyNew Modality (Biologics)Peptide (Design Engineering, Long-acting Peptide)Novel Target Discovery Platform
Selected companies will gain access to ATLATL’s world-class laboratory infrastructure, entrepreneurial resources, and industry mentorship. In addition, awardees will have the opportunity to engage with Samsung Bioepis through its open innovation platform, enabling scientific collaboration, technology assessment, and potential future partnership opportunities. Together, these resources are designed to accelerate innovation and support the translation of promising technologies toward commercialization.
“Innovation thrives when visionary science is matched with the right support and opportunities,” said Min Jeong Seo, Vice President and Leader of Open Innovation Team at Samsung Bioepis. “Through the Innovation Prize, we are seeking to empower promising biotech entrepreneurs and researchers who are advancing novel approaches to address unmet medical needs. By fostering collaboration across the Asia-Pacific region, we hope to help accelerate scientific innovation and contribute to a strong ecosystem for the development of future medicines.”
“Great science alone does not create successful biotech companies,” said Dr. PC Zhu, Founder and CEO of ATLATL. “Innovators need access to world-class infrastructure, R&D ecosystem, experienced mentors, strategic partners, and capital to move forward. By bringing together Samsung Bioepis’ global development expertise and ATLATL’s innovation ecosystem, we hope to provide early-stage biotech entrepreneurs with the resources and support needed to accelerate innovation and deliver meaningful impact to patients.”
The Samsung Bioepis Innovation Prize C-Lab Outside reflects both organizations’ commitment to advancing open innovation and supporting the next generation of biotechnology entrepreneurs. By bringing together scientific talent, development expertise, and critical infrastructure, the program aims to accelerate the translation of breakthrough research into transformative therapies for patients worldwide. The Innovation Prize is also part of Samsung Bioepis C-Lab Outside, Samsung Bioepis’ open innovation program designed to discover, nurture, and collaborate with competent and prospective biotech ventures and startups in and outside of Korea.
About ATLATL
As a global innovation platform for life science research and development, ATLATL has established research centers in Beijing, Shanghai, Shenzhen, Singapore, Hong Kong, and other strategic locations.
ATLATL provides clients with comprehensive research and development services covering various stages, including in vitro drug screening, in vivo disease model establishment, and efficacy evaluation. ATLATL also supports key applications such as large molecule, small molecule, nucleic acid drugs, gene and cell therapy, drug delivery, as well as cutting-edge fields like multi-omics, gene editing, organoids, and organ-on-a-chip. Additionally, ATLATL provides an outstanding experimental environment and professional operational management for scientific researchers.
Through in-depth cooperation with leading global enterprises and research institutions, ATLATL continuously integrates research and development resources and promotes the sharing of new technologies. With advanced systematic research and development models, ATLATL accelerates the engineering process of life sciences, enabling scientific research results to be rapidly and efficiently translated into clinical practice, and contributing to life science innovation and public health on a global level.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/atlatl-and-samsung-bioepis-launch-samsung-bioepis-innovation-prize-c-lab-outside-to-accelerate-early-stage-biotech-innovation-across-asia-pacific-302809136.html
SOURCE ATLATL
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
VANCOUVER, BC, June 24, 2026 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHC) (OTCQB: OHCFF), a digital healthcare technology company focused on developing artificial intelligence (“AI”) health diagnostic solutions, is pleased to announce, further to its news releases dated May 21, 2026 and June 19, 2026, the appointment of Dallas Fontaine to the board of directors of the Company (the “Board”) as the nominee of MV Capital LP (the “Investor”) pursuant to the investor rights agreement entered into in connection with the Company’s recently completed C$5,000,000 secured convertible debenture unit financing.
Dallas Fontaine – Board Director: Mr. Dallas Fontaine is an entrepreneur, technology executive, and investor with extensive experience scaling technology businesses, driving revenue growth, and supporting emerging companies through commercialization and capital formation. He currently serves as Chief Executive Officer of Mountain Vista Capital, where he leads investment and strategic advisory initiatives focused on high-growth technology companies.
Mr. Fontaine is also Co-Founder of ScaleLabs.dev, a software development and innovation company that partners with startups and growth-stage organizations to accelerate product development and market execution. Throughout his career, he has held leadership positions across technology, sales, operations, and business development, helping companies navigate rapid growth and strategic transformation.
Previously, Mr. Fontaine served as Director of Sales at CTO.ai, where he worked with enterprise customers to accelerate software development workflows and operational efficiency through automation technologies. He has also held executive leadership positions in family-owned and private enterprises, overseeing operations, revenue growth initiatives, and organizational expansion.
Mr. Fontaine brings to Light AI a combination of capital markets experience, operational leadership, technology commercialization expertise, and strategic growth execution. His background in scaling innovative technology companies and working closely with founders, investors, and management teams will support Light AI’s transition from development-stage operations toward regulatory approvals, commercialization, and long-term shareholder value creation.
“We are pleased to welcome Dallas Fontaine to the Board of Directors of Light AI,” said John R. Luna, Chief Executive Officer of Light AI Inc. “Dallas brings valuable experience in technology innovation, business growth, capital markets, and scaling emerging companies. As we advance toward commercialization of our QuickScan™ platform and continue executing on our strategic objectives, his perspective and expertise will be an important addition to our Board.”
“On behalf of the Company, I would also like to thank MV Capital LP for its confidence in Light AI through its participation in our recently completed secured convertible debenture unit financing. We look forward to working closely with Dallas as MV Capital’s representative on the Board and value the partnership and support of MV Capital as we pursue our mission of transforming healthcare diagnostics through artificial intelligence and machine learning software.”
About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)
Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI QuickScan™ is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Its cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.
In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (“GAS”). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (“RHD”), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smart device images can be expanded to other medical conditions, as well as other areas of analysis. Light AI’s vision is to combine the Light AI QuickScan™ software platform with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.
ON BEHALF OF THE COMPANY
“John R. Luna”
Chief Executive Officer
Telephone: 1-(888) 804-9459
Email: jluna@light.ai
Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth
Forward-Looking Information:
This news release contains statements and information that, to the extent that they are not historical fact, constitute “forward-looking information” within the meaning of applicable securities legislation, including statements relating to the anticipated contributions of Dallas Fontaine as a director and the advancement of the Company’s business. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, but not limited to, statements relating to the Company’s financial performance, business development, results of operations, and those listed in filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.
SOURCE Light AI Inc.
Technology
Corgi Launches Digital Assets Coverage Endorsement for Directors and Officers Liability Insurance
Published
1 hour agoon
June 24, 2026By
New endorsement affirms D&O coverage for organizations engaged in cryptocurrency, stablecoins, and other digital asset operations
SAN FRANCISCO, June 24, 2026 /PRNewswire/ — Corgi, the AI-native insurance carrier built for startups, today announced the launch of its Digital Assets Coverage Endorsement, a new policy enhancement designed to provide greater clarity and certainty for companies operating in the digital asset ecosystem.
The endorsement expressly affirms coverage under Directors and Officers (D&O) Liability Insurance for claims arising from organizations who have digital asset operations, including activities involving cryptocurrencies.
As digital asset businesses continue to mature, many founders and executives face uncertainty around how traditional insurance policies respond to emerging technologies and business models. The Digital Assets Coverage Endorsement is designed to address that uncertainty by explicitly recognizing digital asset operations within the scope of covered activities.
“Digital asset companies have spent years navigating an insurance market that often treated blockchain businesses as exceptions,” said Emily Yuan, CEO and co-founder of Corgi. “We believe insurance should evolve alongside innovation. This endorsement provides founders, boards, and investors with greater confidence that their insurance coverage reflects the realities of how modern technology companies operate.”
The endorsement defines digital assets broadly to include blockchain-based and distributed ledger-based tokens, cryptocurrencies, stablecoins, and other virtual assets, regardless of how they are classified under applicable law.
Importantly, the endorsement clarifies that an organization’s participation in digital asset operations, by itself, does not trigger policy exclusions. Coverage remains subject to all other policy terms, conditions, exclusions, retentions, and limits.
The launch reflects Corgi’s continued expansion into emerging technology risks and its commitment to building insurance products that align with the needs of innovative companies.
About Corgi
Corgi is an AI-native insurance carrier built for startups and high-growth technology companies. By combining proprietary underwriting technology, in-house claims handling, and modern insurance infrastructure, Corgi helps businesses secure coverage faster and manage risk more effectively as they scale.
Media Contact
Erika Lee
View original content:https://www.prnewswire.com/news-releases/corgi-launches-digital-assets-coverage-endorsement-for-directors-and-officers-liability-insurance-302809823.html
SOURCE Corgi
ATLATL and Samsung Bioepis Launch ‘Samsung Bioepis Innovation Prize C-Lab Outside’ to Accelerate Early-Stage Biotech Innovation Across Asia-Pacific
Light AI Appoints Director
Corgi Launches Digital Assets Coverage Endorsement for Directors and Officers Liability Insurance
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Coin Market5 days agoPhilippine SEC signals readiness for RWA tokenization
-
Coin Market4 days agoCrypto industry looks to stablecoins and DeFi revisions in MiCA 2.0
-
Technology5 days agoREPT BATTERO Deepens Inter Milan Partnership, Brings Latest Innovations to Intersolar Europe 2026
-
Technology5 days agoFelicitysolar Strengthens Brand Presence at SNEC 2026
-
Near Videos5 days agoNEAR Legion Build City NYC: Agentic Dreamwalls
-
Technology4 days agoHelloNation Article Examines Full Coverage Auto Insurance With Insurance Expert Ben Buenzow
-
Coin Market5 days agoPudgy Penguins expands retail footprint with Target trading card rollout
-
Technology4 days agoHelloNation Clarifies Ohio Waiver Waiting List Classifications For Adults With Disabilities, Featuring Home Healthcare Expert Kellan Roberts Of Canton, Ohio
